Use of GLP-1 mimetic in type 2 diabetes mellitus: is it the end of fragility fractures?

Endocrine. 2015 Feb;48(1):1-2. doi: 10.1007/s12020-014-0461-1. Epub 2014 Oct 28.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Fractures, Bone / epidemiology*
  • Fractures, Bone / etiology*
  • Humans
  • Hypoglycemic Agents / adverse effects*
  • Receptors, Glucagon / agonists*

Substances

  • Hypoglycemic Agents
  • Receptors, Glucagon